Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRC-063 Safety and Efficacy in ADHD
NCT02168127Phase 3Completed
- Sponsor
- Rhodes Pharmaceuticals
- Start
- May 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Rhodes Pharmaceuticals. Started May 2014; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02168127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168127.